Physician profile
Sonya Alyea
NPI 1023203734
$5,776.74
in general payments reported to CMS, 2019-2025
29 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $1,048 · 2023: $1,563 · 2024: $1,187 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,031 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,030.51 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,534.22 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $755.94 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $643.13 | 2021-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $499.24 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $314.77 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $306.17 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $233.29 | 2022-2023 | Ocaliva |
| Gilead Sciences, INC. | $178.42 | 2022-2025 | |
| Pfizer INC. | $158.04 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $144.56 | 2021-2023 | |
| Medtronic, INC. | $131.64 | 2021 | |
| Qol Medical, LLC | $112.78 | 2023-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $82.56 | 2021-2023 | Rebyota |
| Madrigal Pharmaceuticals | $76.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $70.27 | 2024-2025 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $69.32 | 2021-2023 | Linzess |
| Organon LLC | $65.92 | 2024-2025 | Renflexis, Hadlima |
| Ardelyx, INC. | $62.42 | 2025 | Ibsrela |
| Lilly USA, LLC | $56.15 | 2025 | Omvoh |
| Celgene Corporation | $53.77 | 2022-2024 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.45 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $29.70 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $27.26 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $25.17 | 2023 | Idacio |
| Braintree Laboratories, INC. | $25.01 | 2022 | |
| Bausch & Lomb Americas INC. | $19.16 | 2022 | |
| Lucid Diagnostics INC. | $18.23 | 2024 | |
| Mauna Kea Technologies, INC. | $17.95 | 2021 | |
| Daiichi Sankyo INC. | $16.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Alyea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.